Taysha Gene Therapies, Inc.
Income Statement
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Revenue | $9.8M | $8.3M | $15.5M | $2.5M |
| Cost of Revenue | — | — | — | — |
| Gross Profit | — | — | — | — |
| Gross Margin | — | — | — | — |
| Operating Expenses | ||||
| Research & Development | $86.4M | $66.0M | $56.8M | $91.2M |
| SG&A Expense | $33.9M | $29.0M | $30.0M | $37.4M |
| Operating Income | $-110.5M | $-91.5M | $-72.4M | $-162.4M |
| Operating Margin | -1,130.6% | -1,097.6% | -468.8% | -6,492.7% |
| Interest Expense | — | — | $5.0M | $3.8M |
| Pretax Income | — | — | — | — |
| Income Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | $-109.0M | $-89.3M | $-111.6M | $-166.0M |
| Net Margin | -1,115.3% | -1,071.6% | -722.1% | -6,635.3% |
| EPS (Basic) | $-0.34 | $-0.36 | $-0.48 | $-0.63 |
| EPS (Diluted) | $-0.34 | $-0.36 | $-0.48 | $-0.63 |
| Shares Outstanding (Basic) | 319.7M | 250.1M | 232.2M | 263.7M |
| Shares Outstanding (Diluted) | 319.7M | 250.1M | 232.2M | 263.7M |
| Dividends Per Share | — | — | — | — |